MedTrace Logo

Syndecan 1 as Biomarker for Inflammation

NCT02333526 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2019-02-12

No results posted yet for this study

Summary

The aim of the study is to evaluate the soluble biomarker syndecan-1 (sSdc1) taken from venous blood of patients with infectious intestinal diseases such as Clostridium difficile-associated colitis, bacterial colitis, Norovirus enteritis and Crohn´s disease or ulcerative colitis. The level of sSdc1 will be compared with disease activity in patients with active inflammation and with disease in remission. Secondary objectives were the assessment of correlation of the above-mentioned factors with the CRP value. Subjects will be volunteers. Blood will be taken as part of the routine clinical work-up after the written agreement blood and sSdc1-level will be assessed using a human-specific sSdc1 ELISA assay. In addition, the subjects are asked to answer a short questionnaire. The study is designed as a prospective, comparative cohort study.

Conditions

Sponsors & Collaborators

  • Helios Albert-Schweitzer-Klinik Northeim

    lead OTHER

Principal Investigators

  • Tobias Meister, PD Dr.med. · Helios Albert-Schweitzer-Klinik Northeim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-31
Primary Completion
2019-12-31
Completion
2020-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02333526 on ClinicalTrials.gov